Erleada™ 60 mg Apalutamide Tablets for Prostate Cancer | Janssen | No Style Like
Original price was: EGP74164.EGP59000Current price is: EGP59000.
Available on backorder
Introduction
Prostate cancer remains one of the most common cancers among men worldwide, significantly affecting quality of life and overall survival rates. With advances in oncology, new therapies have emerged that offer hope and improved outcomes. Among these innovative treatments is Erleada™ 60 mg (Apalutamide), an androgen receptor inhibitor developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Erleada has become a breakthrough therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Its mechanism of action, safety profile, and proven clinical efficacy make it a cornerstone in prostate cancer management.
In this comprehensive article, we explore everything you need to know about Erleada: its uses, mechanism, dosage, side effects, precautions, clinical benefits, drug interactions, and patient experiences.
What is Erleada™ 60 mg?
Erleada is an oral medication containing the active substance Apalutamide, classified as a selective androgen receptor inhibitor. It is specifically designed to block the effects of male hormones (androgens), which play a crucial role in fueling the growth of prostate cancer cells.
By inhibiting androgen receptor signaling, Erleada slows tumor progression, reduces the risk of metastasis, and significantly improves survival outcomes in patients with advanced prostate cancer.
Mechanism of Action
Apalutamide binds directly to androgen receptors and prevents androgens from activating them. This:
Stops the signaling pathway that promotes tumor growth.
Inhibits cancer cell proliferation and spread.
Provides therapeutic benefit without the need for chemotherapy in certain patients.
Indications (Uses of Erleada™)
Erleada is prescribed for:
Non-metastatic castration-resistant prostate cancer (nmCRPC) – men whose prostate cancer continues to progress despite androgen deprivation therapy (ADT), but without detectable metastases.
Metastatic castration-sensitive prostate cancer (mCSPC) – men with newly diagnosed metastatic prostate cancer that still responds to hormonal therapy.
Dosage & Administration
Recommended dose: 240 mg daily (equivalent to 4 tablets of 60 mg each).
Taken orally, once daily, with or without food.
Tablets should be swallowed whole with water.
Must be continued alongside androgen deprivation therapy (ADT) or surgical castration.
Important: Treatment should only be initiated and supervised by an oncologist or healthcare professional experienced in prostate cancer therapy.
Side Effects
Like all medications, Erleada may cause side effects. The most common include:
Fatigue and weakness
Skin rash
High blood pressure (hypertension)
Joint or muscle pain
Increased risk of fractures
Rare: seizures
➡️ Patients are advised to undergo regular monitoring of blood pressure, bone health, and neurological function during treatment.
Precautions & Warnings
Use with caution in patients with a history of seizures or conditions predisposing to seizures.
May increase the risk of falls and bone fractures – bone health management is recommended.
Not indicated for women or children.
Patients should use effective contraception as Apalutamide can harm an unborn child.
Drug Interactions
Erleada may interact with several medications, including:
Anticonvulsants (e.g., phenytoin, carbamazepine)
Statins (cholesterol-lowering drugs)
Thyroid medications (levothyroxine)
Antifungals (ketoconazole, itraconazole)
➡️ Always inform your doctor about all medicines and supplements you are taking before starting Erleada.
Clinical Benefits of Erleada™
Clinical trials have demonstrated that Erleada:
Delays metastasis: Prolongs metastasis-free survival by more than 2 years in nmCRPC.
Extends overall survival: Patients treated with Erleada showed significantly improved survival rates.
Reduces disease progression: Slows cancer growth, delaying the need for chemotherapy.
Maintains quality of life: Effective with manageable side effects.
Storage Instructions
Store below 30°C.
Keep in original packaging, away from light and moisture.
Keep out of reach of children.
Internal Links (for WooCommerce interlinking)
Customer Reviews ⭐⭐⭐⭐⭐
⭐ Ahmed M.: “After 6 months of using Erleada, my PSA levels dropped significantly. The side effects were manageable and overall I feel more stable.”
⭐ John K.: “A breakthrough therapy that gave me hope when other treatments were failing. Although it’s expensive, the results justify it.”
⭐ Mohamed R.: “I’ve been on Erleada for nearly a year. My cancer progression has slowed dramatically, and my doctor is satisfied with the outcome.”
10 Frequently Asked Questions (FAQs)
1. What is Erleada used for?
It is used for the treatment of advanced and non-metastatic castration-resistant prostate cancer.
2. How does Erleada work?
It blocks androgen receptors, preventing male hormones from stimulating prostate cancer cells.
3. How should I take Erleada?
Four 60 mg tablets (240 mg total) once daily, with or without food.
4. Do I need to continue ADT while taking Erleada?
Yes, androgen deprivation therapy must be continued.
5. Can women take Erleada?
No, it is not indicated for women or children.
6. Does Erleada cause infertility?
Yes, it may affect male fertility. Contraception is recommended during and after treatment.
7. What should I do if I miss a dose?
Take it as soon as you remember. If it’s nearly time for the next dose, skip the missed dose. Do not double dose.
8. How long will I need to take Erleada?
Treatment duration depends on your doctor’s assessment of disease progression and tolerance.
9. Can I drink alcohol while on Erleada?
Moderate alcohol may be allowed, but it’s best to consult your doctor.
10. Is Erleada available in Egypt?
Yes, Erleada is registered under EDA Reg. No. 32480/2013 and available through specialized pharmacies.
